In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.
Patients with KMT2Ar acute leukemia, who until now have lacked a therapy targeting their condition, may have hope with news of phase 2 results for revumenib, which blocks the protein interactions that put cells on the path to developing into leukemia.
Ibrahim T. Aldoss, MD, a hematologist/oncologist at City of Hope National Medical Center, presented results Tuesday for AUGMENT-101 (NCT04065399), which is evaluating revumenib in a pair of leukemias, during the late-breaking session of the 65th American Society of Hematology Annual Meeting and Exposition (ASH) in San Diego, California.
Revumenib, developed by Syndax, is being studied in several related blood disorders, with results presented earlier during ASH. Preliminary efficacy and safety were previously demonstrated in a phase 1 study, described in Nature, that examined both relapsed/refractory (R/R) KMT2Ar and nucleophosmin 1-mutated (NPM1m) acute leukemias. At the late-breaking session, Aldoss presented results from an interim analysis for R/R KMT2Ar acute leukemia.
Patients in the trial with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.
This could be quite a turn of events for these patients: right now, those diagnosed with histone-lysine N-methyltransferase 2A (KMT2A)-rearranged acute leukemia are treated with chemotherapy and hematopoietic stem cell transplant (HSCT), but nearly all relapse; complete remission rates are quite low at 5%.
As Aldoss reminded the audience during the late-breaking session, KMT2Ar accounts for 10% of all acute leukemias, and is the most common type of acute leukemia in children.
“It's a disease with unmet therapeutic needs,” Aldoss said in a press briefing prior to the late-breaking session. “These patients are at high risk of relapse after transplant and after chemotherapy.”
He elaborated in an interview with The American Journal of Managed Care®. “There have been different attempts at targeting therapy for KMT2A, but so far, nothing has shown to be effective. So, we’re very excited by revumenib, because it is already showing us, in patients who have chemorefractory disease, have relapsed, and are heavily pretreated, that a single agent is able to actually achieve responses in these patients with a manageable safety profile.”
Mechanism of Action. As Aldoss explained, acute leukemia occurs when menin interacts with KMT2A, driving cell behavior during the immature phase, causing the cells’ failure to differentiate and become active. When this happens, the immature cells also take the space of healthy cells. Revumenib targets menin to disrupt the interaction that triggers this process, he said, allowing “the immature ones to become actually mature, healthy, functioning cells.”
The concept of blocking the mechanism that prevents differentiation is not new, but it can cause adverse effects known as differentiation syndrome (DS). Thus, AUGMENT-101 would seek not only to evaluate efficacy but also safety including whether DS occurs in patients receiving the drug.
Methods. Patients diagnosed at least 30 days prior with R/R KMT2Ar acute leukemia were enrolled in cohort A, which was mixed phenotype acute leukemia (MPAL); cohort B, which was acute myeloid leukemia (AML), or cohort C, which continues to enroll patients with NPMIm and will be reported later. Patients received 163 mg of revumenib (or 95 mg/m2, if they weighed less than 40 kg) every 12 hours with an antibiotic in 28-day cycles. Treatment continued until unacceptable toxicity or lack of at least morphological leukemia-free state after 4 cycles.
Primary endpoints were safety and tolerability of revumenib and complete response (CR) plus complete response with partial hematological recovery (CRh). Key secondary endpoints included the composite CR rate (CRc), the CRc with incomplete platelet recovery (CRp), the CRc with incomplete count recovery (CRi), and overall response rate (ORR).
A planned interim analysis (IA) of pooled adult and pediatric patients took place. The 94 patients evaluated as of July 24, 2023, after receiving at least 1 dose of the study drug were included in the safety analysis. According to the abstract, the IA efficacy analysis included all patients in phase 2 with centrally confirmed KMT2Ar acute leukemia and at least 5% blasts in the bone marrow at baseline who received at least 1 dose of study drug before the 38th adult AML efficacy evaluable patient The IA was specified to occur when 57 patients had been followed for 6 months.
Results. The results of the safety analysis were as follows:
Results from the interim efficacy analysis were as follows:
Aldoss said revumenib is being studied in combination with other therapies and also in earlier lines of care. “The next step is, how can we better combine this agent with other standard treatments? How can we give it more post-transplant to reduce the risk of relapse?”
Giving it to patients in earlier lines of care could prove critical; in response to a question, Aldoss said that patients who had received venetoclax had much lower response rates than those who had not received this therapy.
In a statement, officials from Syndax said they remain on track to submit a New Drug Application to FDA for revumenib for the treatment of R/R KMT2Ar acute leukemia by the end of the year.
Reference
Aldoss I, Issa GC, Thirman M, et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal augment-101 phase 2 study. Presented at: 65th American Society of Hematology Annual Meeting and Exposition, San Diego, CA: December 9-12, 2023. Abstract LBA-5.
.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More